DSIP lacks credible modern human clinical trial evidence supporting its use as a sleep therapeutic. Delta sleep-inducing peptide was named for what it did in laboratory animals. Human insomnia trials followed in the 1980s and 1990s. Those clinical investigations were small. Their own authors described the measured improvements as clinically insignificant. In the United States, no government-approved pharmaceutical product contains this molecule. The compound remains unapproved.
The Verdict
What the DSIP Sleep Studies Measured
Controlled human trials testing DSIP for insomnia found that the peptide produced minor changes that failed to achieve clinical significance. Two double-blind studies in diagnosed insomniacs make up that record, and both sets of investigators said so themselves: the 1987 crossover trial concluded that "sleep improvement under DSIP treatment is of little clinical significance", and its figures are set out with the 1992 study further down this page.
That verdict matters more than the direction of the numbers. Sleep latency and awakenings did move, and the people who ran the trials still judged the movement too small to matter to a patient. A compound named for inducing delta sleep has never cleared that bar in a modern trial.
The Animal Origin of the Delta Sleep Name
The name came from a 1984 review's summary of animal experiments, not from a human trial. A 1984 review characterized delta sleep-inducing peptide as a nonapeptide containing nine amino acids with a molecular weight of 849. That review summarized early findings across several species. The authors stated that the peptide "induces mainly delta-sleep in rabbits, rats, mice, and humans, whereas in cats, the effect on REM sleep was more pronounced." However, the experimental procedures behind those animal observations involved delivery mechanisms that differ entirely from consumer administration.
Consider the animal methodology. A 1987 study in cats tested the peptide's effects on feline sleep architecture. Researchers administered an intraventricular dose of the molecule. An intraventricular dose is delivered directly into the brain ventricles of an animal. Following this intraventricular injection, the cats showed a significant decrease in sleep latency. They also exhibited significant increases in total sleep time and total slow-wave sleep. The researchers recorded no change in REM sleep.
These results demonstrated that injecting the peptide directly into central nervous system tissue altered animal brain wave activity. Yet an intracranial injection in an animal model does not represent human administration.
Human Insomnia Studies and Author Conclusions
Two human insomnia trials make up the entire controlled clinical record for this peptide, and the table below is the whole of it. No large-scale, adequately powered, modern randomized controlled trial of DSIP exists on the scientific record.
| Study and Year | Design and Cohort | Measured Sleep Changes | Authors' Published Conclusion |
|---|---|---|---|
| 1987 Double-Blind Crossover Study | Crossover trial in chronic insomniacs | Fewer nighttime awakenings and shorter sleep latency | "No significant differences were found in comparison to baseline or to double-blind placebo nights" and "sleep improvement under DSIP treatment is of little clinical significance" |
| 1992 Double-Blind Study | Parallel study in 16 patients with insomnia | Shorter sleep latency and higher sleep efficiency versus placebo | Effects judged weak; short-term administration "is not likely to be of major therapeutic benefit" |
Endogenous Rhythm Findings and the Mechanical Conflict
Circulating levels of DSIP in the human body fluctuate in direct opposition to the timing of natural slow-wave sleep. If a peptide acts as the body's natural trigger for deep delta sleep, circulating levels should peak during slow-wave episodes. A 1994 study investigated this exact physiological relationship in 12 healthy human volunteers. Researchers tracked plasma DSIP-like immunoreactivity alongside body temperature and sleep stages. The findings contradicted the proposed mechanism.
The researchers observed that plasma DSIP-like immunoreactivity followed a clear daily circadian rhythm. This rhythm correlated positively with core body temperature. Furthermore, plasma DSIP-like immunoreactivity correlated negatively with both REM sleep and slow-wave sleep.
Most decisively, the authors observed that DSIP-like levels "did not rise before, during, or after" a significant share of slow-wave-sleep episodes. The peptide did not surge to initiate delta waves. It did not elevate while delta waves occurred. This inverse correlation creates a substantial physiological problem for the delta-inducing hypothesis. The body's own chemical levels drop during the precise sleep stages that marketing claims the peptide promotes.
FDA Evaluation of Emideltide and Compounding Status
The United States Food and Drug Administration (FDA) addresses DSIP under the established nonproprietary name emideltide on its compounding safety dockets. A reader searching agency records under the acronym DSIP will not locate the official entry. The agency reviews the molecule as emideltide. On its page titled "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," the agency lists "Emideltide (DSIP)" under the specific heading "Bulk drug substances nominated but withdrawn." FDA notes that these substances were "previously in category 2 of the interim policies [that] were withdrawn by the nominators." The page was current as of 22 April 2026.
The agency's published safety assessment identifies specific concerns regarding the compound. FDA issued the following statement regarding the substance: "Compounded drugs containing emideltide may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified safety-related information regarding emideltide for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans."
This regulatory language outlines two distinct technical issues. First, the agency highlighted immunogenicity risks. Immunogenicity refers to the risk that the body mounts an immune response to the injected peptide. Second, the agency noted complexities involving active pharmaceutical ingredient (API) characterization and manufacturing impurities. Because safety data for clinical administration routes remains absent, FDA lacks evidence showing whether the substance causes harm. Currently, there is no FDA-approved drug containing DSIP. The peptide does not appear on FDA bulk drug lists permitted for compounding, nor does it sit in the active Category 2 table. At Longevity Benchmark, we read the federal compounding tables and the trial authors' own conclusions before the vendor copy. For more on how those classifications work, see our overview of peptide therapy FDA regulatory status.
Clinical Evidence Needed to Re-Evaluate DSIP
Overturning the historical assessment of DSIP would require modern, prospective, preregistered clinical trials demonstrating measurable therapeutic benefits. The existing literature rests entirely on studies conducted more than three decades ago. Those trials enrolled cohorts too small to establish statistical power or detect rare adverse outcomes.
A valid clinical reassessment would need modern, registered trials that also resolve the impurity and characterisation concerns FDA named, in an adequately powered sample of diagnosed chronic insomniacs. Patients would need to undergo registered clinical trials with polysomnography as the endpoint. The measured improvements would also need to exceed double-blind placebo responses by a clinically meaningful margin. Until such trials appear in peer-reviewed medical journals, the evidence base remains limited to historical pilot studies whose authors found little clinical benefit.
- API characterization and purity. Resolving the peptide-related impurity and characterisation complexities FDA named for emideltide.
- Human immunogenicity screening. Measuring whether the injected peptide provokes an immune response, the risk FDA flagged and no trial on the record has tested.
- Adequately powered participant cohorts. Adequately powered trials rather than the small cohorts of at most a few dozen people evaluated in early studies.
- Objective polysomnographic endpoints. Polysomnography as the endpoint in adequately powered, registered trials.
Frequently Asked Questions
Is DSIP peptide FDA approved?
No, DSIP is not approved by the Food and Drug Administration (FDA) for any medical condition or therapeutic use. The agency evaluates the compound under its nonproprietary name, emideltide. In its safety dockets regarding bulk drug substances used in compounding, FDA lists emideltide under substances nominated but withdrawn by their nominators. The agency noted that compounded preparations containing emideltide may pose risks for immunogenicity and present manufacturing complexities regarding peptide impurities and active ingredient characterization. Furthermore, the agency has not identified safety information for proposed administration routes. Because sufficient evidence is lacking to determine whether the compound causes harm, no approved commercial pharmaceutical product containing DSIP exists in the United States.
Does DSIP peptide help with sleep?
Clinical evidence showing that DSIP helps human sleep is weak and inconclusive. While early animal studies showed sleep alterations following direct intracranial injections into brain ventricles, human trials conducted in the 1980s and 1990s demonstrated minimal therapeutic impact. In a 1987 double-blind crossover study of chronic insomniacs, investigators found that sleep improvements under DSIP did not significantly differ from baseline or placebo conditions. The study authors concluded that the peptide's effects were of little clinical significance. Similarly, a 1992 double-blind study of 16 patients observed modest reductions in sleep latency but concluded that short-term administration was not likely to provide major therapeutic benefit. Natural human chronobiology research also shows that endogenous DSIP levels drop during slow-wave sleep.
What is delta sleep-inducing peptide?
Delta sleep-inducing peptide (DSIP) is a nonapeptide composed of nine amino acids with a molecular weight of 849. A 1984 review characterized the peptide. Early laboratory experiments suggested that the peptide induced slow-wave delta sleep in small animals, particularly when administered directly into the cerebral ventricles of the brain. The substance is known as emideltide in regulatory and pharmaceutical classifications. While early hypotheses suggested the peptide acted as an endogenous sleep regulator, subsequent human chronobiology research demonstrated that circulating levels of the peptide actually correlate negatively with slow-wave sleep and REM sleep, declining during the deep sleep phases it was named after.
Does DSIP peptide work?
Scientific trials indicate that DSIP does not produce clinically meaningful improvements in human sleep architecture. The strongest evidence evaluating whether the peptide works comes from the primary investigators of human insomnia trials. In a 1987 double-blind study, researchers noted that while patients experienced fewer nighttime awakenings and shorter latency, the changes were not statistically significant compared to placebo nights. The authors concluded that the clinical benefit was insignificant. In a 1992 double-blind trial evaluating 16 patients, authors noted weak improvements in sleep latency and efficiency, concluding that short-term treatment lacked major therapeutic value. There are no modern, adequately powered clinical trials showing that the compound effectively treats sleep disorders.
Is DSIP peptide safe?
The human safety profile of DSIP is not established in scientific literature or regulatory reviews. In its review of bulk drug substances for compounding, the Food and Drug Administration noted that emideltide may pose risks for immunogenicity, which is the potential for an injected peptide to trigger an unwanted immune response. The agency also cited complexities surrounding peptide-related impurities and active pharmaceutical ingredient characterization. FDA stated that it had not identified safety-related information regarding emideltide for proposed administration routes and lacked sufficient information to determine whether the drug would cause harm in humans. Because human trials have been limited to small historical pilot studies, comprehensive safety and toxicity data remain absent.
Is DSIP peptide legal?
In the United States, DSIP is not an approved medication and does not appear on FDA lists of bulk drug substances permitted for pharmacy compounding. On FDA compounding dockets, the molecule is listed as emideltide under bulk drug substances nominated but subsequently withdrawn by their nominators. It was previously categorized under Category 2 of interim compounding policies before nomination withdrawal. Regulatory records current as of April 2026 show that it does not sit on the active Category 2 list or the approved compounding list. There is no FDA-approved DSIP product.
Is DSIP peptide addictive?
Scientific literature does not provide data on whether DSIP peptide possesses addictive potential or causes physiological dependence. The cited studies did not measure dependence.
Does DSIP peptide make you tired?
Published human studies do not establish that DSIP reliably produces acute tiredness or daytime sedation. While a 1992 trial reported modest reductions in sleep latency compared to placebo, the authors characterized the biological effect as weak and insufficient for major therapeutic benefit. Furthermore, a 1994 study of 12 volunteers found that plasma DSIP-like immunoreactivity correlated positively with body temperature and negatively with REM and slow-wave sleep. The cited studies did not measure next-day sedation.
Related
- Peptide therapy FDA regulatory status and safety dockets
- Deep sleep versus REM sleep architecture differences
- How much deep sleep adults need each night
- How sleep tracker scores evaluate sleep architecture
- Magnesium glycinate clinical evidence for insomnia
- Best deep sleep supplement formulations and evidence